Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP769382.RAmlicTDuLtKVO0n5wJR2mF5aC9XYmcS2qocSY-0SOgZE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP769382.RAmlicTDuLtKVO0n5wJR2mF5aC9XYmcS2qocSY-0SOgZE130_assertion type Assertion NP769382.RAmlicTDuLtKVO0n5wJR2mF5aC9XYmcS2qocSY-0SOgZE130_head.
- NP769382.RAmlicTDuLtKVO0n5wJR2mF5aC9XYmcS2qocSY-0SOgZE130_assertion description "[They also argue that combining PI3K/AKT/mTOR inhibitors with BH3 mimetics warrants attention in AML, particularly in the setting of basal AKT activation and/or addiction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP769382.RAmlicTDuLtKVO0n5wJR2mF5aC9XYmcS2qocSY-0SOgZE130_provenance.
- NP769382.RAmlicTDuLtKVO0n5wJR2mF5aC9XYmcS2qocSY-0SOgZE130_assertion evidence source_evidence_literature NP769382.RAmlicTDuLtKVO0n5wJR2mF5aC9XYmcS2qocSY-0SOgZE130_provenance.
- NP769382.RAmlicTDuLtKVO0n5wJR2mF5aC9XYmcS2qocSY-0SOgZE130_assertion SIO_000772 23243017 NP769382.RAmlicTDuLtKVO0n5wJR2mF5aC9XYmcS2qocSY-0SOgZE130_provenance.
- NP769382.RAmlicTDuLtKVO0n5wJR2mF5aC9XYmcS2qocSY-0SOgZE130_assertion wasDerivedFrom befree-20140225 NP769382.RAmlicTDuLtKVO0n5wJR2mF5aC9XYmcS2qocSY-0SOgZE130_provenance.
- NP769382.RAmlicTDuLtKVO0n5wJR2mF5aC9XYmcS2qocSY-0SOgZE130_assertion wasGeneratedBy ECO_0000203 NP769382.RAmlicTDuLtKVO0n5wJR2mF5aC9XYmcS2qocSY-0SOgZE130_provenance.